Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Simon M. Helfgott, MD  |  Issue: January 2016  |  January 19, 2016

About 15 years ago, a couple of food microbiologists observed that following infection the bacterial genome of certain streptococcal species integrated a sequence of the viral genome, called a spacer. This sequence served as a guide for destroying any matching DNA so that subsequent viral infections were fended off. Bacteria use this system naturally, and dairy food scientists wanted to harness it to immunize bacterial starter cultures against phage infection, a huge source of product contamination, affecting 2% of cheese production worldwide.4 In 2012, the DuPont Chemical company of Wilmington, Del., the patent holder of CRISPR-enhanced starter cultures, announced its first commercial application that could make pizza cheese consistently taste the same. It dubbed the blend of S. thermophilus strains that were used, CHOOZIT SWIFT. Given DuPont’s share of the dairy culture market, estimated to be about 50%, the chances are quite good that you have already eaten CRISPR-modified food.4 Buon appetito!

CRISPR/Cas9 is considered to be among the simplest genome-editing tools to work with because it relies on RNA–DNA base pairing, rather than the engineering of proteins that bind particular DNA sequences. This has transformed the field overnight. It used to take at least three generations of progeny to create a knockout mouse carrying the altered genetic material; with CRISPR, both gene copies are edited simultaneously, so a knockout rodent can be created in a single generation. The process has become so straightforward that an edited gene can be produced in a matter of days.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In the past, it was a student’s entire PhD thesis to change one gene,” remarks Bruce Conklin, MD, professor of medicine at the University of California in San Francisco. “CRISPR just knocked that out of the park.”5

Talk about speed: Cas9 must identify a short three-base-pair DNA sequence immediately following the primer sequence, dubbed PAM, which occurs about 300 million times within the human genome. For it to be effective though, it must work at lightning speed, because recent studies have indicated that as many as 300,000 bindings may occur before the correct sequence of DNA is cut.6

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers have traditionally relied heavily on model organisms, such as mice and fruit flies, partly because they were the only species that came with a good toolkit for genetic manipulation. Now CRISPR is making it possible to edit genes in many more organisms. Researchers have begun using CRISPR to develop better biofuels and to create new enzymes for industrial markets, where they are used in laundry detergents, water treatment and paper milling. In agriculture, companies are using the system to make crops more resistant to pests and drought, without using genes spliced in from other species, such as a flounder gene inside a tomato. Livestock breeders can harness it to produce animals with more muscle mass and leaner meat, faster and more predictably than with ordinary crossbreeding.5

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:discoverygenegenomeimpactpublic healthscience

Related Articles

    U.S. Scientists Unveil Powerful New Tools to Fix Genetic Faults

    October 26, 2017

    CHICAGO (Reuters)—U.S. scientists on Wednesday unveiled two new molecular editing tools designed to fix mutations that cause the majority of human genetic diseases, some of which have no known treatment. One technique, by David Liu of Harvard University and the Broad Institute of MIT and Harvard, offers a highly precise way to fix single-letter mistakes…

    Technological Advances Linked to Medical Misadventures

    April 15, 2016

    For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences